Market share and costs of biologic therapies for inflammatory bowel disease in the USA

Summary Background Real‐world data quantifying the costs of increasing use of biologics in inflammatory bowel disease ( IBD ) are unknown. Aim To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9‐year period. Methods The Truven MarketScan ® Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis (UC) during 2007‐2015. National drug codes were used to identify...